Revolution Medicines, Inc. Banner Image

Revolution Medicines, Inc. has reached its limit for free report views

Work for Revolution Medicines, Inc.? Upgrade Your Profile and unlock all your annual reports.

Revolution Medicines, Inc.

  • Ticker RVMD
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Revolution Medicines, Inc. Logo Image
  • 51-200 Employees
  • Based in Redwood City, California
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. Their most advanced product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2More, a central node in the RAS signaling pathway. In collaboration with their partner, Sanofi, they are evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types featuring specific oncogenic mutations. Additionally, they are developing a portfolio of mutant-selective RAS inhibitors that they believe are the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). Their pipeline also includes inhibitors of other frontier oncology targets within the RAS and mTOR pathways. These include SOS1 and 4EBP1/mTORC1, with a development candidate for the latter, RMC-5552, currently advancing into IND-enabling studies.
4.8 / 5.0 (118)

Revolution Medicines, Inc. reports have an aggregate usefulness score of 4.8 based on 118 reviews.

Revolution Medicines, Inc.

Most Recent Annual Report

Revolution Medicines, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. Revolution Medicines, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Revolution Medicines, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!